Albireo Pharma Inc ROCE
¿Qué es el ROCE de Albireo Pharma Inc?
El ROCE de Albireo Pharma Inc es -43.59%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en NASDAQ en comparadas con Albireo Pharma Inc
¿Qué hace Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Empresas con roce similar a Albireo Pharma Inc
- Apyx Medical tiene ROCE de -43.78%
- HUTCHMED (China) tiene ROCE de -43.71%
- Goodrich Petroleum tiene ROCE de -43.68%
- Stoke Therapeutics tiene ROCE de -43.66%
- Adverum Biotechnologies Inc tiene ROCE de -43.65%
- Ultragenyx Pharmaceutical tiene ROCE de -43.61%
- Albireo Pharma Inc tiene ROCE de -43.59%
- e-Play Digital tiene ROCE de -43.44%
- e-Therapeutics Plc tiene ROCE de -43.43%
- Western Metallica Resources Cor tiene ROCE de -43.42%
- Petros Pharmaceuticals tiene ROCE de -43.21%
- European Assets Trust Plc tiene ROCE de -43.17%
- StartEngine Crowdfunding tiene ROCE de -43.17%